B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

AGTR2

MOLECULAR TARGET

angiotensin II receptor type 2

UniProt: P50052NCBI Gene: 1869 compounds

AGTR2 (angiotensin II receptor type 2) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting AGTR2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1telmisartan4.2972
2Losartan3.2224
3saralasin2.8316
4l 1588092.8316
5buloxibutid2.6413
6losartan potassium2.208
7olodanrigan1.956
8Irbesartan1.102
9candesartan cilexetil [Supplementary Concept]0.691

About AGTR2 as a Drug Target

AGTR2 (angiotensin II receptor type 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented AGTR2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

AGTR2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.